Nutra Pharma Corp (NPHC) Total Current Liabilities (2010 - 2026)

Nutra Pharma has disclosed Total Current Liabilities across 17 years of filings, most recently posting $21.7 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 31.07% year-over-year to $21.7 million; the TTM figure through Jun 2026 stood at $21.7 million (up 31.07% YoY), while the FY2025 annual figure was $17.3 million, up 13.39% from the prior year.
• Total Current Liabilities came in at $21.7 million for Q2 2026 at Nutra Pharma, up from $17.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $21.7 million in Q2 2026 to a low of $12.7 million in Q4 2022.
• Average Total Current Liabilities over 5 years is $15.8 million, with a median of $15.7 million recorded in 2022.
• Year-over-year, Total Current Liabilities plunged 60.89% in 2022 and surged 31.07% in 2026.
• Over 5 years, Total Current Liabilities stood at $12.7 million in 2022, then grew by 11.58% to $14.2 million in 2023, then increased by 7.73% to $15.3 million in 2024, then rose by 13.39% to $17.3 million in 2025, then rose by 25.33% to $21.7 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $21.7 million in Q2 2026, $17.7 million in Q1 2026, and $17.3 million in Q4 2025.